Koshinski Asset Management Inc. Sells 388 Shares of Revvity, Inc. (NYSE:RVTY)

Koshinski Asset Management Inc. reduced its holdings in shares of Revvity, Inc. (NYSE:RVTY) by 5.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,837 shares of the company’s stock after selling 388 shares during the quarter. Koshinski Asset Management Inc.’s holdings in Revvity were worth $873,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in RVTY. Rothschild Investment LLC bought a new position in Revvity in the second quarter valued at $25,000. EverSource Wealth Advisors LLC increased its position in shares of Revvity by 74.2% in the second quarter. EverSource Wealth Advisors LLC now owns 392 shares of the company’s stock valued at $41,000 after acquiring an additional 167 shares during the last quarter. Family Firm Inc. bought a new stake in Revvity during the second quarter worth about $43,000. Fairfield Financial Advisors LTD acquired a new position in Revvity during the second quarter valued at approximately $43,000. Finally, EntryPoint Capital LLC bought a new position in Revvity in the first quarter valued at approximately $48,000. 86.65% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

RVTY has been the topic of a number of analyst reports. Jefferies Financial Group upped their price objective on Revvity from $115.00 to $125.00 and gave the stock a “hold” rating in a research note on Monday, July 29th. Wells Fargo & Company started coverage on shares of Revvity in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $130.00 price target for the company. Barclays boosted their price objective on shares of Revvity from $115.00 to $125.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 30th. Bank of America upped their target price on shares of Revvity from $118.00 to $127.00 and gave the company a “neutral” rating in a report on Tuesday, July 30th. Finally, JPMorgan Chase & Co. boosted their price target on Revvity from $105.00 to $120.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 30th. Eight analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $125.53.

Insider Buying and Selling at Revvity

In related news, insider Tajinder S. Vohra sold 2,153 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $122.09, for a total value of $262,859.77. Following the transaction, the insider now owns 23,960 shares in the company, valued at approximately $2,925,276.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Tajinder S. Vohra sold 2,154 shares of the company’s stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $121.73, for a total transaction of $262,206.42. Following the completion of the sale, the insider now owns 19,652 shares of the company’s stock, valued at approximately $2,392,237.96. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Tajinder S. Vohra sold 2,153 shares of Revvity stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $122.09, for a total transaction of $262,859.77. Following the completion of the transaction, the insider now directly owns 23,960 shares in the company, valued at $2,925,276.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 7,807 shares of company stock valued at $937,576 in the last three months. Corporate insiders own 0.60% of the company’s stock.

Revvity Stock Up 1.2 %

RVTY opened at $122.91 on Tuesday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.98 and a current ratio of 2.27. The stock has a fifty day moving average of $121.42 and a 200-day moving average of $112.63. Revvity, Inc. has a fifty-two week low of $79.50 and a fifty-two week high of $128.15. The company has a market capitalization of $15.17 billion, a P/E ratio of 101.58, a P/E/G ratio of 3.35 and a beta of 1.05.

Revvity (NYSE:RVTY) last posted its quarterly earnings data on Monday, July 29th. The company reported $1.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $0.10. Revvity had a net margin of 6.26% and a return on equity of 7.34%. The firm had revenue of $691.70 million during the quarter, compared to the consensus estimate of $690.33 million. During the same quarter in the previous year, the firm posted $1.21 EPS. The business’s revenue for the quarter was down 2.5% compared to the same quarter last year. On average, equities analysts expect that Revvity, Inc. will post 4.75 EPS for the current year.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 8th. Shareholders of record on Friday, October 18th will be paid a dividend of $0.07 per share. The ex-dividend date is Friday, October 18th. This represents a $0.28 dividend on an annualized basis and a yield of 0.23%. Revvity’s dividend payout ratio (DPR) is presently 23.14%.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.